3SBio (1530) Stock Overview
An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
1530 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
3SBio Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$34.98 |
| 52 Week High | HK$35.70 |
| 52 Week Low | HK$5.47 |
| Beta | 0.73 |
| 1 Month Change | 17.15% |
| 3 Month Change | 45.75% |
| 1 Year Change | 507.29% |
| 3 Year Change | 513.68% |
| 5 Year Change | 312.99% |
| Change since IPO | 274.12% |
Recent News & Updates
Analysts Just Shipped A Substantial Upgrade To Their 3SBio Inc. (HKG:1530) Estimates
Sep 03
Estimating The Fair Value Of 3SBio Inc. (HKG:1530)
Sep 01Recent updates
Analysts Just Shipped A Substantial Upgrade To Their 3SBio Inc. (HKG:1530) Estimates
Sep 03Estimating The Fair Value Of 3SBio Inc. (HKG:1530)
Sep 01Should You Be Adding 3SBio (HKG:1530) To Your Watchlist Today?
Aug 15There's Reason For Concern Over 3SBio Inc.'s (HKG:1530) Massive 26% Price Jump
Jun 30The Compensation For 3SBio Inc.'s (HKG:1530) CEO Looks Deserved And Here's Why
Jun 18Analysts Just Published A Bright New Outlook For 3SBio Inc.'s (HKG:1530)
May 26Are Investors Undervaluing 3SBio Inc. (HKG:1530) By 42%?
May 21Solid Earnings Reflect 3SBio's (HKG:1530) Strength As A Business
May 073SBio Inc. (HKG:1530) Stock Rockets 36% As Investors Are Less Pessimistic Than Expected
Apr 243SBio (HKG:1530) Has Announced A Dividend Of CN¥0.25
Apr 173SBio (HKG:1530) Will Pay A Dividend Of CN¥0.25
Mar 313SBio Inc. (HKG:1530) Released Earnings Last Week And Analysts Lifted Their Price Target To HK$10.80
Mar 303SBio Inc. (HKG:1530) Soars 27% But It's A Story Of Risk Vs Reward
Mar 103SBio Inc. (HKG:1530) Screens Well But There Might Be A Catch
Jan 173SBio's (HKG:1530) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Oct 083SBio Inc.'s (HKG:1530) P/E Is Still On The Mark Following 34% Share Price Bounce
Oct 07We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt
Sep 26Shareholder Returns
| 1530 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 16.8% | 6.5% | 0.4% |
| 1Y | 507.3% | 192.1% | 46.0% |
Return vs Industry: 1530 exceeded the Hong Kong Biotechs industry which returned 192.1% over the past year.
Return vs Market: 1530 exceeded the Hong Kong Market which returned 46% over the past year.
Price Volatility
| 1530 volatility | |
|---|---|
| 1530 Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in HK Market | 15.8% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 1530 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1530's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 6,268 | Jing Lou | www.3sbio.com |
3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER2. It also offers Yisaipu, the receptor fusion tumor necrosis factor inhibitor; EPIAO and SEPO, an erythropoietin injection; Mandi-minoxidil, an OTC external medicine for treating hair loss; and SPARIN, an injectable low-molecular-weight heparin calcium.
3SBio Inc. Fundamentals Summary
| 1530 fundamental statistics | |
|---|---|
| Market cap | HK$85.30b |
| Earnings (TTM) | HK$2.58b |
| Revenue (TTM) | HK$9.91b |
Is 1530 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1530 income statement (TTM) | |
|---|---|
| Revenue | CN¥9.07b |
| Cost of Revenue | CN¥1.33b |
| Gross Profit | CN¥7.75b |
| Other Expenses | CN¥5.39b |
| Earnings | CN¥2.36b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.99 |
| Gross Margin | 85.37% |
| Net Profit Margin | 25.99% |
| Debt/Equity Ratio | 9.7% |
How did 1530 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/08 15:27 |
| End of Day Share Price | 2025/09/08 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
3SBio Inc. is covered by 37 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Difei Yang | Capstone Investments |
| Bo Yu | China International Capital Corporation Limited |
| Zhuhong Chen | China Merchants Securities (HK) Co., Ltd |